All News
Running with Data (8.30.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com - including tips on steroids, MAS, and myositis testing.
Read Article
All in the Family (8.23.2024)
Dr. Jack Cush picks highlight reports from the past week on RheumNow.com, with reports on the challenge of lupus nephritis, perplexing skin issues, you don't know JAK (about Tyk) and the value of a good family history.
Read Article
Depends on Where You’re Looking (8.9.2024)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week.
Read Article
Different Autoantibody Phenotypes in Juvenile and Adult Myositis
A Kyoto University study compared juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM patients, demonstrating different autoantibody profiles and a more favorable outcome for n juvenile-IIM patients.… https://t.co/fHL14rXAQ6 https://t.co/ZagRU62joJ
Dr. John Cush RheumNow ( View Tweet)
Congratulations to UCF Associate Professor Justine Tigno-Aranjuez for receiving prestigious U.S. National Science Foundation CAREER Award on her research into NOD2 receptor signaling of lipid mediators contributing to inflammation https://t.co/AkUZbdTSqF https://t.co/usTe2bzyXE
Dr. John Cush RheumNow ( View Tweet)
REAL-HLH, a retrospective study of emapalumab (anti-IFNg) was effective in Rheum (15 pts) w/ hemophagocytic lymphohistiocytosis (10 w/ Still's disease, 60% in ICU w/ refractory Dz). EMA normalized CXCL9, ANC, decr steroids & had 12 mo survival=87% https://t.co/MgYul9rCqV https://t.co/pDpriVvAdg
Dr. John Cush RheumNow ( View Tweet)
Singapore study of Autoimmune (AIRD) risk w/ COVID infx compared 104 179 DELTA + pts vs 666 575 PCR neg controls (~80+% Vax) & 375 903 Omicron+ vs 619 379 controls (~75% boosted). Found no signif incr risk of AIRD w/ COVID infx. https://t.co/gXzWdotzvL https://t.co/UsQpwgsyTD
Dr. John Cush RheumNow ( View Tweet)
Biomarker subanalysis of a phase 3 RCT of SC Abatacept in 219 polyarticular JIA pts. Lower baseline levels of S100A8/9 & S100A12 predicted better response (JIA-ACR90 2.5) at 16 mos. Decr in S100A8/9 & S100A12 @4mos was >50% among responders https://t.co/TWx62EhRBl https://t.co/6uhoRowg3n
Dr. John Cush RheumNow ( View Tweet)
Karolinska genotyping study of 329 JIA pts (oligo 161, Seroneg Poly 87, Seropos poly 12, Stills 24, ERA 22, PsA 19). HLA-DRB1*08 linked to JIA total; The HLA-DRB1*11 to Oligo; ANA+ JIA linked to HLA-DRB1-DQA1-DQB1, HLA-DRB1*11, & HLA-DPB1*02 https://t.co/1yNawNTEys https://t.co/dmmlH0CvRi
Dr. John Cush RheumNow ( View Tweet)
Novel: 2 case reports of refractory macrophage activation syndrome successfully treated w/ an investigational monoclonal Ab (MAS825 ) to IL-1β, and IL-18 https://t.co/ZqC77njbjk https://t.co/13W8RZIiRZ
Dr. John Cush RheumNow ( View Tweet)
Causes of Carpal Tunnel Syndr: obesity, repetitive wrist movements, pregnancy, RA, PsA. but also Sjögren's syndrome, Behcet's disease and systemic sclerosis (weaker) https://t.co/ssrs8UJEpX
Dr. John Cush RheumNow ( View Tweet)
Cohort of 112 VEXAS pts: skin involvement common (83%), esp early w/ LCV (36%), neutrophilic (34%) or perivascular dermatitis (30%). p.Met41Leu variant w/ PMN (Sweets?) dermatitis (82%); p.Met41Val variant w/ vasculitic lesions (55%). 92% respond to pred https://t.co/2ACXCGRsi5 https://t.co/tYqA26AlaF
Dr. John Cush RheumNow ( View Tweet)
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome - genetic disease with estimated prevalence of 1 in 4269 in men >50 year: systemic inflammation, progressive bone marrow failure, and inflammatory cutaneous manifestations https://t.co/hSmE64xzcU https://t.co/gWh4rvaaS3
Dr. John Cush RheumNow ( View Tweet)
JAKi an option for Still's Dz, especially refractory AOSD? Metanlysis of 9 studies (35 pts), Rx w/ either Tofa (17), Bari (14), Ruxo (4), Upa 1. Half had complete remission, 1/3 partial remission, 1/5 loss effect. Ruxolitinib 100% effective in AOSD w/ MAS https://t.co/3TKFNsj4v9 https://t.co/3yAXlcJ2sX
Links:
Dr. John Cush RheumNow ( View Tweet)
New! 📣Best Practice Guidelines for the management of Haemophagocytic Lymphohistiocytosis (HLH) aka Macrophage Activation Syndrome (MAS) from @NHSGIRFT @RheumatologyUK Remember the 3Fs Fever, Falling Counts, Ferritin and follow the HLH pathway to guide management… https://t.co/8oDyUbsm9W https://t.co/S0MDi3TkNk
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Retrospective study from Univ of Tokyo on 194 Behcets dz (BD) pts, found 25% who developed intestinal BD (meanF/U 12 yrs). Use of #PPI significantly incr risk of intestinal BD (adj HR 2.48; vs non-PPI), w/ a confirmed duration/dose-dependent relationship. https://t.co/qFeS8svMLj https://t.co/KT8OBrY96S
Dr. John Cush RheumNow ( View Tweet)
Full Read Overview of the safety of bDMARDs/tsDMARDS - contraindications, precautions, & boxed warnings for treatment of RA, PsA, SpA, JIA - safety checklist for a class of drugs you use and diseases you treat https://t.co/5chrS3sW8i https://t.co/twSv4Zs9r3
Links:
Dr. John Cush RheumNow ( View Tweet)
Lit review of ILD in anti-synthetase syndrome finds no conclusive evidence of effective treatment. 10 studies, 514 pts (68% female); Hi Res CT positive in 87% w/ 49% having NSIP pattern. 48% Jo-1+, 28% Ro52+. Low improvements w/ RTX (12%), CYC (17%). https://t.co/oJ0EMAE7d0 https://t.co/bDiA1h9hO7
Dr. John Cush RheumNow ( View Tweet)
Systematic review: RX of macrophage activation syndr (MAS), included 57 reports, 1148 MAS pts (889 sJIA, 137 SLE). Most effective was high-dose GCs, IL-1 (83%) & IFNγ (93%) inhibitors, especially in sJIA-MAS. Also Ciclosporin, etoposide, Ruxolitinib https://t.co/4EnMOnlcYl https://t.co/PQnAZLvVwq
Dr. John Cush RheumNow ( View Tweet)
Inpatient study 5495 Adult Stills Dz (AOSD) hospitalizations (2016–2019). Pts w/ HLH (6.2%) had higher mortality (9% vs 1.5%). Deatjs Independent predictors: DIC (OR 6.1), liver failure (7.2), Infx (3.7), resp failure (6.9),thrombotic microangiopathy (14) https://t.co/BQsbVnw2Ir https://t.co/mbn9JuN7ow
Dr. John Cush RheumNow ( View Tweet)
